Murray Goulburn Co-operative Co Limited

Agriculture Victoria Services Pty Limited

Saputo Dairy Australia Pty Limited

Murray Goulburn Co-operative., Limited

Flsmidth A/s

Andrew Brown

Peter Hobman

Michelle Rowney

Benjamin Graeme Cocks

Matthew McDonagh

Angus Tester

Jonathan David Buckley

Kurt O'Bryan, Sr

Matthew Mcdonagh

Yu Pan

Richard Paine

Kurt O'bryan

The invention provides a method of treating a disorder characterised by elevated or dysregulated myostatin, disorders where the interaction between follistatin and angiogenin can be used to improve function in tissues, neurological diseases or disorders, spinal injuries or diseases, bone diseases or disorders, diseases involving glucose homeostasis, wound healing, neuroprotection, nervous system functional support or managing metabolic diseases, the method comprising administering an effective amount of angiogenin or an angiogenin agonist. Compositions and neutraceuticals comprising angiogenin are also provided.

Use of angiogenin or angiogenin agonists for treating diseases and disorders

The invention provides a process for purifying lactoferrin from milk, the process comprising subjecting the milk to filtration to separate it into a retentate fraction comprising lactoferrin and a permeate fraction comprising growth factors and/or RNAses, wherein prior to and/or during filtration the milk is subjected to salt treatment such that growth factors and/or RNAses flow into the permeate. The invention also provides lactoferrin obtained from the process of the invention and uses thereof.

Process for purifying lactoferrin from milk and products thereof

The invention provides a method for treating cancer in a subject or a method of inducing an anti-tumour effect including reducing tumour volume, inhibiting or slowing tumour growth, inhibiting tumour progression, altering the metabolic activity of a tumour, inducing quiescence of a tumour, inhibiting or reducing metastasis, inhibiting or reducing tumour invasiveness, reducing tumour weight, reducing tumour neovascularisation, improving time to disease progression (TDP) and/or improving survival, the method comprising administering to the subject an effective amount of angiogenin or an angiogenin agonist.

Methods of treating cancer using angiogenin or an angiogenin agonist

The invention provides a method of treating a disorder characterized by elevated or dysregulated myostatin, disorders where the interaction between follistatin and angiogenin can be used to improve function in tissues, neurological diseases or disorders, spinal injuries or diseases, bone diseases or disorders, diseases involving glucose homeostasis, wound healing, neuroprotection, nervous system functional support or managing metabolic diseases, the method comprising administering an effective amount of angiogenin or an angiogenin agonist. Compositions and neutraceuticals comprising angiogenin are also provided.

The present invention relates to a formulation comprising whey protein or a hydrolysate of whey protein, which formulation is capable of inhibiting the expression of TNF&#x3b1; in lipopolysaccharide-stimulated macrophages in vitro. Also provided are uses of the formulation for attenuating a reduction in muscle function which results from muscle damage and/or for enhancing recovery from muscle damage and/or for enhancing the force generating capacity of muscle and methods of making the formulation.

Formulation comprising whey protein and hydrolysates for improving muscle recovery

The invention provides methods for enriching a milk extract for angiogenin, such methods involving separation by size, charge or immunoaffinity. The invention also provides the angiogenin enriched extract produced by the methods and provides them in pharmaceutical and neutraceutical compositions and foods for treating a variety of diseases or disorders that can be treated by angiogenin.

Angiogenin-enriched milk fractions

The invention provides a process for the preparation of an angiogenin-enriched fraction from a milk product, the process comprising contacting the milk product with a cation exchange resin and eluting the angiogenin-enriched fraction from the cation exchange resin with a mobile phase. The invention also provides angiogenin-enriched fractions produced by process and food products, nutraceuticals and pharmaceutical comprising such angiogenin.

Process for the preparation of angiogenin

The invention relates to the production of compositions containing IgA for use as a food additive. More specifically, it relates to a process to prepare an IgA-enriched milk product extract composition and to such compositions.

Growing community of inventors

Cobram, Australia

Andrew Brown